Inferior
发表于 2025-3-23 11:26:39
http://reply.papertrans.cn/17/1675/167430/167430_11.png
GNAW
发表于 2025-3-23 15:36:41
Špela Orehek,Gregor Petrič,Jan ŠinigojAlthough the mechanism of onset of lung injuries induced by drugs has not been clearly identified, it has been generally accepted that the pathologic condition occurs through direct cellular damages or indirect ones by inflammatory reactions, an immunological mechanism, by drugs or their intermediate metabolites .
left-ventricle
发表于 2025-3-23 19:28:45
http://reply.papertrans.cn/17/1675/167430/167430_13.png
eucalyptus
发表于 2025-3-23 22:56:16
http://reply.papertrans.cn/17/1675/167430/167430_14.png
亲密
发表于 2025-3-24 02:35:55
http://reply.papertrans.cn/17/1675/167430/167430_15.png
套索
发表于 2025-3-24 10:07:56
HCI International 2020 - PostersAs a result of clinical studies, interstitial pneumonia is listed among important toxic events associated with the use of neoangiogenesis inhibitors. This information is included in the package insert. In this section, sunitinib, sorafenib, and bevacizumab, which were investigated in the post-marketing all-case survey are explained.
树木心
发表于 2025-3-24 12:05:34
Exposure Compensation from a Single ImageThe drug was used as an ALK inhibitor clinically at its first approval, and since then the indications have been expanded.
狂怒
发表于 2025-3-24 15:50:00
http://reply.papertrans.cn/17/1675/167430/167430_18.png
Antimicrobial
发表于 2025-3-24 19:39:09
Anti-EGFR Antibodies (Cetuximab, Panitumumab, and Necitumumab)Study period: September 2008–January 2009 .
dilute
发表于 2025-3-25 02:57:12
Proteasome Inhibitor (Bortezomib)Bortezomib (Velcade) was approved for the production and sale on October 20, 2006, and was launched on December 1, 2006. At that time, this drug was placed as a specific medicine for multiple myeloma.